Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Last trade$1.48
Day change-$0.12 (-7.50%)
Day range$1.48 – $1.68
Volume1,020,855
Market cap$157M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$157.23M
Price / earnings
—
Price / book
0.77×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.89×
Profitability
Earnings per share
-$1.44
Return on assets
-52.43%
Return on equity
-69.14%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.33×
Quick ratio
7.33×
Cash ratio
0.74×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$133.87M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ZNTL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$26.87M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$26.87M
Selling, general and administrative
$8.82M
$9.23M
$9.14M
$7.91M
$10.78M
$8.45M
$10.58M
$40.01M
Research and development
$22.33M
$35.16M
$28.72M
$29.49M
$22.95M
$27.61M
$27.25M
$32.97M
Total operating expenses
$31.15M
$44.39M
$37.86M
$37.39M
$33.73M
$36.06M
$45.62M
$76.71M
Operating income
-$31.15M
-$44.39M
-$37.86M
-$37.39M
-$33.73M
-$36.06M
-$45.62M
-$49.85M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$28.7M
-$42.15M
-$35.23M
-$34.77M
-$26.69M
-$26.87M
-$48.28M
-$47.68M
Income taxes
$118K
$138K
$120K
$442K
$0
$0
$0
-$205K
Net income
-$28.82M
-$42.29M
-$35.35M
-$35.22M
-$26.69M
-$26.87M
-$48.28M
-$47.47M
Net income attributable to common shareholders
-$28.82M
-$42.29M
-$35.35M
-$35.22M
-$26.69M
-$26.87M
-$48.28M
-$47.47M
EBITDA
-$31M
-$44.24M
-$37.7M
-$37.24M
-$33.57M
-$35.9M
-$37.57M
-$45.8M
Basic earnings per share
-$0.34
-$0.59
-$0.50
-$0.49
-$0.37
-$0.37
-$0.67
-$0.67
Diluted earnings per share
-$0.34
-$0.59
-$0.50
-$0.49
-$0.37
-$0.37
-$0.67
-$0.67
Recent news
Company coverage with links to the original publishers.
Zentalis Pharmaceuticals granted non-qualified stock options to purchase 136,000 shares to four newly hired employees on November 2, 2026, with an exercise price of $1.85 per share. The options vest over four years under the company's 2022 Inducement Plan.
Zentalis Pharmaceuticals announced interim overall survival data from the DENALI Part 1b study of azenosertib, its investigational WEE1 inhibitor for platinum-resistant ovarian cancer. In Cyclin E1-positive patients (n=48), median OS was 15.8 months compared to 7.5 months in Cyclin E1-negative patients (n=46). The company concluded that Cyclin E1 is a highly selective biomarker for azenosertib response, with OS data comparing favorably to historical chemotherapy benchmarks, supporting continued development in Phase 3 trials.
Over 25 companies are developing 32+ pipeline drugs for osteosarcoma treatment, with significant focus on innovative approaches including Phase III product HS-20093 (B7-H3-targeted ADC), TGF-β1 inhibitors, and CAR-T therapies. The report highlights strong R&D activity and substantial unmet medical needs in this primary malignant bone tumor space.
Zentalis Pharmaceuticals granted non-qualified stock options for 191,000 shares to two newly hired employees at an exercise price of $3.98 per share. The company is strengthening its commercial leadership team and advancing its registrational program for azenosertib, a first-in-class WEE1 inhibitor, in platinum-resistant ovarian cancer treatment.
Zentalis Pharmaceuticals granted 26,000 non-qualified stock options to a newly hired employee on May 1, 2026, with an exercise price of $4.09 per share under the 2022 Inducement Plan. The options have a 10-year term and vest over four years, subject to continued employment.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.